BMPPB-32 is a highly selective LRRK2 inhibitor. References: Cording AC, Shiaelis N, Petridi S, Middleton CA, Wilson LG, Elliott CJH. Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease. NPJ Parkinsons Dis. 2017 Dec 4;3:34. doi: 10.1038/s41531-017-0036-y. eCollection 2017. PubMed PMID: 29214211; PubMed Central PMCID: PMC5715132.

纯度：≥98%